A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study

BACKGROUND: A phase 2, randomized, placebo-controlled trial was conducted in women with recurrent epithelial ovarian carcinoma to evaluate the efficacy and safety of motolimod—a Toll-like receptor 8 (TLR8) agonist that stimulates robust innate immune responses—combined with pegylated liposomal doxor...

Descripción completa

Detalles Bibliográficos
Autores principales: Monk, B. J., Brady, M. F., Aghajanian, C., Lankes, H. A., Rizack, T., Leach, J., Fowler, J. M., Higgins, R., Hanjani, P., Morgan, M., Edwards, R., Bradley, W., Kolevska, T., Foukas, P., Swisher, E. M., Anderson, K. S., Gottardo, R., Bryan, J. K., Newkirk, M., Manjarrez, K. L., Mannel, R. S., Hershberg, R. M., Coukos, G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Original articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406764/
https://www.ncbi.nlm.nih.gov/pubmed/28453702
http://dx.doi.org/10.1093/annonc/mdx049

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406764/
https://www.ncbi.nlm.nih.gov/pubmed/28453702
http://dx.doi.org/10.1093/annonc/mdx049

Ejemplares similares